Fujirebio’s Vision for the Future of Blood-Based Biomarkers: How It Plans to Change Neurological Disease Diagnosis

For decades, diagnosing neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and ALS often meant waiting until symptoms became obvious. By then, significant brain damage had already occurred.

Fujirebio believes the future will look very different.

The company’s vision is simple yet ambitious: make blood-based biomarker testing as routine as cholesterol or diabetes testing, allowing neurological diseases to be detected earlier, monitored more easily, and treated more effectively.

This vision is increasingly important as neurological disorders continue to rise worldwide. According to global health estimates, more than 55 million people live with dementia today, and that number is expected to reach nearly 139 million by 2050. Alzheimer’s disease accounts for roughly 60–70% of all dementia cases.

From Complex Brain Testing to a Simple Blood Draw

Historically, confirming Alzheimer’s disease required expensive PET scans or invasive spinal taps.

These procedures are effective but difficult to scale globally. Many patients never receive them due to cost, accessibility, or availability of specialists.

Fujirebio’s long-term strategy focuses on replacing these barriers with accessible blood-based diagnostics.

A major milestone came in 2025 when the FDA cleared Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test—the first FDA-cleared blood-based in-vitro diagnostic test for identifying amyloid pathology associated with Alzheimer’s disease.

The test measures two key biomarkers linked to Alzheimer’s disease and provides results from a standard blood sample rather than a brain scan or lumbar puncture.

The Bigger Goal: Earlier Detection Means Better Outcomes

Fujirebio is not simply building diagnostic tests.

The company is trying to move neurological care upstream—identifying disease before major cognitive decline occurs.

Clinical studies of its FDA-cleared blood test demonstrated:

For physicians, this means faster identification of patients who may benefit from emerging Alzheimer’s therapies.

For patients, it means fewer delays and potentially earlier intervention.

Beyond Alzheimer’s: Building a Complete Neurology Biomarker Portfolio

Many competitors are heavily focused on Alzheimer’s disease alone.

Fujirebio’s vision extends much further.

The company is actively developing and expanding biomarker programs for:

• Parkinson’s disease
• Multiple sclerosis (MS)
• Amyotrophic lateral sclerosis (ALS)
• Lewy body dementia
• Other neurodegenerative disorders

Its neurological biomarker pipeline combines blood biomarkers, cerebrospinal fluid (CSF) biomarkers, automated testing platforms, and companion diagnostics.

This broader disease focus positions Fujirebio as a long-term neurological diagnostics company rather than a single-product Alzheimer’s testing provider.

What Makes Fujirebio Different From Competitors?

The neurological biomarker market is becoming crowded.

Companies such as Roche, Quanterix, Labcorp, and C2N Diagnostics are all investing heavily in blood-based neurological testing.

However, Fujirebio has chosen a different strategy.

Competitor Approach

Many competitors focus on:

• Individual biomarker tests
• Research-use platforms
• Proprietary diagnostic ecosystems
• Alzheimer’s-specific commercialization

Fujirebio Approach

Fujirebio focuses on:

• Full biomarker discovery
• Clinical validation
• FDA-cleared diagnostics
• Global manufacturing
• Partner-enabled commercialization
• Multi-disease neurological portfolios

The company also embraces an open partnership model, working with pharmaceutical firms, research organizations, and diagnostic manufacturers rather than limiting biomarker use to its own platforms.

Investing for the Next Decade of Brain Health

A key part of Fujirebio’s future strategy is continuous innovation.

The company invests approximately 15% of its base revenue into research and development, supporting next-generation biomarker discovery and commercialization.

Recent collaborations with organizations such as Biogen and Beckman Coulter aim to develop new blood-based biomarkers capable of measuring tau pathology directly in the brain; an area many researchers believe will be critical for future Alzheimer’s therapies.

Looking Ahead: A Future Where Brain Health Testing Becomes Routine

Fujirebio’s vision is not merely to create better tests.

Its goal is to transform neurological diagnostics into a routine part of healthcare.

The company envisions a future where a simple blood draw can help identify neurodegenerative disease years before severe symptoms emerge, enabling physicians to monitor progression, select targeted therapies, and improve patient outcomes.

While competitors are racing to launch individual assays, Fujirebio is building an integrated neurological diagnostics ecosystem spanning biomarker discovery, regulatory approval, clinical deployment, and global partnerships.

If successful, the company could play a central role in making blood-based neurological testing the standard of care for millions of patients worldwide over the next decade.